New hope for kids with tough leukemia: Three-Drug combo trial launches

NCT ID NCT06448013

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—in children and young adults (ages 3 to 21) with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. Up to 22 participants will be enrolled at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ziftomenib, venetoclax, and gemtuzumab
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The combination may cause serious side effects or fail to control the leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia mixed phenotype acute leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.